Moderna stock is trading -15.31% below its average target price of $138.52 after dropping -4.4% during today's afternoon session. Analysts are giving the Large-Cap Biotechnology company an average rating of buy and target prices ranging from $60.0 to $310.0 per share.
The stock has an average amount of shares sold short at 7.2%, and a short ratio of 6.93. The company's insiders own 9.6% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 73.0% of Moderna's shares being owned by this investor type.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Baillie Gifford and Company | 12% | 44,655,817 | $5,238,573,783 |
| 2023-12-31 | Vanguard Group Inc | 9% | 33,907,072 | $3,977,638,533 |
| 2023-12-31 | Blackrock Inc. | 7% | 25,301,692 | $2,968,141,426 |
| 2023-12-31 | State Street Corporation | 4% | 14,623,723 | $1,715,508,909 |
| 2023-12-31 | Flagship Pioneering Inc. | 3% | 9,666,038 | $1,133,922,894 |
| 2023-12-31 | Theleme Partners LLP | 2% | 7,349,456 | $862,164,665 |
| 2023-12-31 | Wellington Management Group, LLP | 2% | 7,225,579 | $847,632,654 |
| 2023-12-31 | Geode Capital Management, LLC | 2% | 6,549,461 | $768,317,253 |
| 2023-12-31 | FMR, LLC | 2% | 6,393,351 | $750,003,990 |
| 2023-12-31 | Goldman Sachs Group Inc | 1% | 4,551,626 | $533,951,234 |
Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Moderna.
